tradingkey.logo

Moderna shares slump after FDA refuses to review new flu vaccine

ReutersFeb 10, 2026 11:15 PM

Shares of Moderna MRNA.O fall 8% to ~$39 in extended trading

MRNA says U.S. Food and Drug Administration will not review approval application for its influenza vaccine

Says refusal to review submission is inconsistent with feedback at pre-phase 3 and pre-submission consultations

Says requested a meeting with the Center for Biologics Evaluation and Research to understand basis for refusal

In 2025, MRNA fell over 29%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI